MoneyWorks4Me

Clarification sought from Sanofi India

30 Oct 2015 Evaluate

The Exchange has sought clarification from Sanofi India with reference to news reported on CNBC TV18 on October 29, 2015-‘Setback For Glenmark: Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule.’

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1756.90
Dr. Reddys Labs. 1195.10
Cipla 1303.30
Lupin 1960.00
Zydus Lifesciences 1115.10
View more..